REPORTING STANDARDS AND RESEARCH STRATEGIES FOR CONTROLLED TRIALS - AGENDA FOR THE EDITOR

被引:174
作者
MOSTELLER, F [1 ]
GILBERT, JP [1 ]
MCPEEK, B [1 ]
机构
[1] MASSACHUSETTS GEN HOSP,BOSTON,MA 02114
来源
CONTROLLED CLINICAL TRIALS | 1980年 / 1卷 / 01期
关键词
D O I
10.1016/S0197-2456(80)80006-7
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
引用
收藏
页码:37 / 58
页数:22
相关论文
共 13 条
[1]  
COHEN JV, 1977, STATISTICAL POWER AN
[2]   IMPORTANCE OF BETA, TYPE-II ERROR AND SAMPLE-SIZE IN DESIGN AND INTERPRETATION OF RANDOMIZED CONTROL TRIAL - SURVEY OF 71 NEGATIVE TRIALS [J].
FREIMAN, JA ;
CHALMERS, TC ;
SMITH, H ;
KUEBLER, RR .
NEW ENGLAND JOURNAL OF MEDICINE, 1978, 299 (13) :690-694
[3]  
GILBERT JP, 1977, COSTS RISKS BENEFITS
[4]  
Glass GV, 2016, ED RES, V5, P3, DOI [10.2307/1174772ISSN0536-1036, 10.3102/0013189x005010003, DOI 10.3102/0013189X005010003]
[5]  
Hyman H.H., 1975, ENDURING EFFECTS ED
[6]   CONTROVERSY OVER STUDY OF DIABETES DRUGS CONTINUES FOR NEARLY A DECADE [J].
KOLATA, GB .
SCIENCE, 1979, 203 (4384) :986-990
[7]  
MCPEEK B, 1977, COSTS RISKS BENEFITS
[8]  
MOSTELLER F, 1979, CLIN PHARMACOL THER, V25, P761
[9]  
MOSTELLER F, 1954, HDB SOCIAL PSYCHOLOG, V1
[10]  
Mosteller Frederick, 1972, EQUALITY ED OPPORTUN